Callio Therapeutics

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Callio Therapeutics #Financing #Oncology #Start-ups

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.   Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.  The newly formed company, with headquarters in Seattle and Singapore,… Read More

#Business & Investment #Cancer Research #News #Start-up Zone